Lateral Pharma News Today

Looking for a detailed comparison of AOD-9604 vs. Ipamorelin, including their research history, properties, and mechanism of action? In this ...

Among all the Chronic Pain emerging therapies, Rexlemestrocel (Gruenthal and Mesoblast) is expected to occupy the maximum share of the Chronic Pain market owing to promising efficacy signals shown in the phase II trial and also expected premium pricing.  Interested in knowing more about the report highlights? Get in touch @ Chronic pain is pain, which lasts for more than three months. The pain worsens with time and recurs at undefined periods of time. In normal cases, after healing pain subs...